Recent genomic analyses of AML1-ETO AML patients have identified that the average variant allele frequency of mutations in ASXL2 are significantly higher than those of other mutations frequently co-existing with AML1-ETO such as c-KIT, FLT3 and N/KRAS mutations25. This evidence concerns the gene RUNX1 and acute myeloid leukemia.